Insider Trader Watch: Rockwell Medical, Inc. $RMTI

09176de39ce471de0e163908590fe9a7

Rockwell Medical, Inc. (RMTI) insider have most recently took part in a trading activity. On Aug 10, 2017 Richmond David S., bought 605 shares having total worth of $3,836 at the price of $6.34 per share, following the transaction a total of 516,474 shares owned by Richmond David S.. Before this latest buy, Richmond David S. purchased RMTI at 1 other times during the past twelve months, for a total investment of $217,306 at an average of $5.84 per share.

Furthermore, over the past 12 months , the stock was traded 8 times by insiders. In 7 of these trades, the insider was a seller while an employee of the company was the buyer in 1 instances.

Shares of Rockwell Medical, Inc. (RMTI) traded down 6.05% on Aug 10, 2017, hitting $6.37. 234,238 shares of the company’s stock traded hands. Rockwell Medical, Inc. has a 52 week low of $4.51 and a 52 week high of $10.04. The company’s market cap is $342 million.

Rockwell Medical, Inc. (RMTI) last announced its earnings results on Aug 9, 2017. The company reported -0.14 earnings per share (EPS) for the quarter, lower than the consensus estimate of -0.10 by $0.04. The company had revenue of $13 million for the quarter, compared to the consensus estimate of $13 million. During the same quarter in the previous year, the company posted -0.11 earnings per share. The company’s revenue for the quarter was down 2% on a year-over-year basis.

2017-08-09 2017-05-09 2017-03-15 2016-11-07 2016-08-08 2016-05-10 2016-02-29 2015-11-09 2015-08-04 2015-02-26
earnings per share -0.14 -0.09 -0.10 -0.09 -0.11 -0.09 -0.12 -0.05 -0.05 -0.14
Revenue(M) 13.24 14.59 13.39 12.82 13.45 13.63 14.13 14.38 12.96 14.45

Rockwell Medical Inc was incorporated in the state of Michigan in 1996. The Company is a fully-integrated biopharmaceutical company targeting end-stage renal disease (‘ESRD’) and chronic kidney disease (‘CKD’) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company manufactures, sells, delivers and distributes hemodialysis concentrates, along with a full line of ancillary products, to customers in the U.S. and abroad. Dialysate concentrates account for over 92% of its revenue and consist of two products known in the industry as ‘acid’ and ‘bicarbonate’ and are packaged as liquid or powder. All of its products are manufactured according to AAMI and GMP guidelines. Its concentrate products are used in conjunction and are diluted with clean water on-site at the clinic in the dialysis machine, creating dialysate, which works to clean the patient’s blood. Its CitraPure concentrate is 100% acetate-free, in contrast to the acetate-based products used for many years. Acetate promotes inflammation so its removal is beneficial to the patient. Dry powder acid concentrate for use with its Dry Acid Mixing System, containing acetic acid, sodium chloride, dextrose and electrolyte additives such as magnesium, potassium, and calcium. It supplies dry acid in 25 gallon cases. Its Dry Acid Concentrate Mixing System is designed for its CitraPure and Dri-Sate Dry Acid product and allows a clinic to mix its acid concentrate on-site. The clinic technician, using a specially designed mixer, adds pre-measured packets of the necessary ingredients to purified water (AMII standard). RenalPure bicarbonate sold in powder form is used mainly in chronic settings. Each clinic mixes bicarbonate on-site as required. teriLyte bicarbonate is sold in liquid form and is used mainly in acute care settings. It offer a range of ancillary products including blood tubing, fistula needles, specialized custom kits, dressings, cleaning agents, filtration salts and other supplies used by hemodialysis providers. Its largest competitor is US based Fresenius Medical Care NA, which is mainly in the business of operating dialysis clinics, as well as manufacturing and marketing dialysis devices, drugs and supplies. The testing, manufacture and sale of its hemodialysis concentrates and the ancillary products it distribute are subject to regulation by numerous governmental authorities, principally the FDA and corresponding state and foreign agencies.

William White

William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.

About the Author

William White
William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.